Current multiple myeloma treatment strategies with novel agents: a European perspective.

Détails

Ressource 1Télécharger: BIB_6C9646C3771B.P001.pdf (918.62 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_6C9646C3771B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Périodique
Oncologist
Auteur(s)
Ludwig Heinz, Beksac Meral, Blade Joan, Boccadoro Mario, Cavenagh Jamie, Cavo Michele, Dimopoulos Meletios, Drach Johannes, Einsele Hermann, Facon Thierry, Goldschmidt Hartmut, Harousseau Jean-Luc, Hess Urs, Ketterer Nicolas, Kropff Martin, Mendeleeva Larisa, Morgan Gareth, Palumbo Antonio, Plesner Torben, San Miguel Jesus, Shpilberg Ofer, Sondergeld Pia, Sonneveld Pieter, Zweegman Sonja
ISSN
1549-490X[electronic], 1083-7159[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
15
Numéro
1
Pages
6-25
Langue
anglais
Résumé
The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.
Mots-clé
Multiple Myeloma, Thalidomide, Bortezomib, Lenalidomide, Stem-Cell Transplantation, Lenalidomide Plus Dexamethasone, Newly-Diagnosed Myeloma, Velcade-Thalidomide-Dexamethasone, Bone-Marrow-Transplantation, Randomized Controlled-Trial, Progression-Free Survival, Impaired Renal-Function, High Response Rates, Long-Term Survival
Pubmed
Web of science
Création de la notice
24/02/2010 10:50
Dernière modification de la notice
03/03/2018 18:05
Données d'usage